CDK8 and chronic myelogenous leukemia, BCR-ABL1 positive: In the culture of chronic myeloid leukemia cells, senexin Bincreased the antitumor effect of targeted inhibitors of chimeric tyrosinekinase Bcr-ABL [78], thus broadening thepossibilities of CDK8/19 inhibition in the therapy of blood cancers.